Literature DB >> 19428302

Is complement good or bad for cancer patients? A new perspective on an old dilemma.

Maciej M Markiewski1, John D Lambris.   

Abstract

Several studies of human cancers have established that chronic and insidious inflammation promotes the process of carcinogenesis and exacerbates the growth of existing tumors. Conversely, acute inflammation seems to have the opposite effect. Recent discoveries indicate that this dualism in the role of inflammation in cancer is mirrored by the effects of the complement system on this disease process. Previous studies have suggested that complement proteins can contribute to the immune surveillance of malignant tumors. However, a very recent study has indicated that complement proteins can also promote tumor growth. Here, we describe our current understanding of the role of complement in tumor development and progression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19428302      PMCID: PMC2704572          DOI: 10.1016/j.it.2009.04.002

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  76 in total

Review 1.  Rules for making human tumor cells.

Authors:  William C Hahn; Robert A Weinberg
Journal:  N Engl J Med       Date:  2002-11-14       Impact factor: 91.245

2.  Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid.

Authors:  N Donin; K Jurianz; L Ziporen; S Schultz; M Kirschfink; Z Fishelson
Journal:  Clin Exp Immunol       Date:  2003-02       Impact factor: 4.330

Review 3.  The role of complement in inflammatory diseases from behind the scenes into the spotlight.

Authors:  Maciej M Markiewski; John D Lambris
Journal:  Am J Pathol       Date:  2007-07-19       Impact factor: 4.307

Review 4.  Epstein-Barr virus and oncogenesis: from latent genes to tumours.

Authors:  Lawrence S Young; Paul G Murray
Journal:  Oncogene       Date:  2003-08-11       Impact factor: 9.867

Review 5.  Molecular viral oncology of hepatocellular carcinoma.

Authors:  Timothy M Block; Anand S Mehta; Claus J Fimmel; Robert Jordan
Journal:  Oncogene       Date:  2003-08-11       Impact factor: 9.867

Review 6.  Inflammation and cancer.

Authors:  Lisa M Coussens; Zena Werb
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

7.  Functional receptor for C3a anaphylatoxin is expressed by normal hematopoietic stem/progenitor cells, and C3a enhances their homing-related responses to SDF-1.

Authors:  Ryan Reca; Dimitrios Mastellos; Marcin Majka; Leah Marquez; Janina Ratajczak; Silvia Franchini; Aleksandra Glodek; Marek Honczarenko; Lynn A Spruce; Anna Janowska-Wieczorek; John D Lambris; Mariusz Z Ratajczak
Journal:  Blood       Date:  2003-01-02       Impact factor: 22.113

8.  In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas.

Authors:  Olivier Manches; Gabrielle Lui; Laurence Chaperot; Rémy Gressin; Jean-Paul Molens; Marie-Christine Jacob; Jean-Jacques Sotto; Dominique Leroux; Jean-Claude Bensa; Joël Plumas
Journal:  Blood       Date:  2002-10-03       Impact factor: 22.113

9.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

Authors:  Lin Zhang; Jose R Conejo-Garcia; Dionyssios Katsaros; Phyllis A Gimotty; Marco Massobrio; Giorgia Regnani; Antonis Makrigiannakis; Heidi Gray; Katia Schlienger; Michael N Liebman; Stephen C Rubin; George Coukos
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245

10.  Non-small cell lung cancer cells produce a functional set of complement factor I and its soluble cofactors.

Authors:  Marcin Okroj; Yi-Fan Hsu; Daniel Ajona; Ruben Pio; Anna M Blom
Journal:  Mol Immunol       Date:  2007-06-04       Impact factor: 4.407

View more
  62 in total

Review 1.  Complement: a key system for immune surveillance and homeostasis.

Authors:  Daniel Ricklin; George Hajishengallis; Kun Yang; John D Lambris
Journal:  Nat Immunol       Date:  2010-08-19       Impact factor: 25.606

2.  Sublytic complement protects prostate cancer cells from tumour necrosis factor-α-induced cell death.

Authors:  L Liu; W Li; Z Li; M Kirschfink
Journal:  Clin Exp Immunol       Date:  2012-08       Impact factor: 4.330

3.  Chronic Activation of Innate Immunity Correlates With Poor Prognosis in Cancer Patients Treated With Oncolytic Adenovirus.

Authors:  Kristian Taipale; Ilkka Liikanen; Juuso Juhila; Riku Turkki; Siri Tähtinen; Matti Kankainen; Lotta Vassilev; Ari Ristimäki; Anniina Koski; Anna Kanerva; Iulia Diaconu; Vincenzo Cerullo; Markus Vähä-Koskela; Minna Oksanen; Nina Linder; Timo Joensuu; Johan Lundin; Akseli Hemminki
Journal:  Mol Ther       Date:  2015-08-27       Impact factor: 11.454

Review 4.  Nanoparticles and the immune system.

Authors:  Banu S Zolnik; Africa González-Fernández; Nakissa Sadrieh; Marina A Dobrovolskaia
Journal:  Endocrinology       Date:  2009-12-16       Impact factor: 4.736

5.  Negative control of CSL gene transcription by stress/DNA damage response and p53.

Authors:  Elena Menietti; Xiaoying Xu; Paola Ostano; Jean-Marc Joseph; Karine Lefort; G Paolo Dotto
Journal:  Cell Cycle       Date:  2016-05-10       Impact factor: 4.534

Review 6.  Role of C5b-9 complement complex and response gene to complement-32 (RGC-32) in cancer.

Authors:  Sonia I Vlaicu; Cosmin A Tegla; Cornelia D Cudrici; Jacob Danoff; Hassan Madani; Adam Sugarman; Florin Niculescu; Petru A Mircea; Violeta Rus; Horea Rus
Journal:  Immunol Res       Date:  2013-05       Impact factor: 2.829

Review 7.  The dual role of complement in cancer and its implication in anti-tumor therapy.

Authors:  Ioannis Kourtzelis; Stavros Rafail
Journal:  Ann Transl Med       Date:  2016-07

8.  Complement Inhibition: A Novel Form of Immunotherapy for Colon Cancer.

Authors:  Stephanie Downs-Canner; Deepa Magge; Roshni Ravindranathan; Mark E O'Malley; Lily Francis; Zuqiang Liu; Z Sheng Guo; Natasa Obermajer; David L Bartlett
Journal:  Ann Surg Oncol       Date:  2015-08-20       Impact factor: 5.344

9.  An antimicrobial peptide regulates tumor-associated macrophage trafficking via the chemokine receptor CCR2, a model for tumorigenesis.

Authors:  Ge Jin; Hameem I Kawsar; Stanley A Hirsch; Chun Zeng; Xun Jia; Zhimin Feng; Santosh K Ghosh; Qing Yin Zheng; Aimin Zhou; Thomas M McIntyre; Aaron Weinberg
Journal:  PLoS One       Date:  2010-06-08       Impact factor: 3.240

10.  Blood peptidome-degradome profile of breast cancer.

Authors:  Yufeng Shen; Nikola Tolić; Tao Liu; Rui Zhao; Brianne O Petritis; Marina A Gritsenko; David G Camp; Ronald J Moore; Samuel O Purvine; Francisco J Esteva; Richard D Smith
Journal:  PLoS One       Date:  2010-10-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.